FemTech biotech & women's health

01Overview and value chain

Markers: [EC: EU Gender Equality Strategy & IVDR 2017/746 | OECD: Biotech & health — women’s health biotechnology | Regulator: FDA (USA), EMA (EU), NMPA (China)]

FemTech biotech develops biologics, drugs and diagnostics for conditions that affect exclusively or disproportionately women, targeting a medical gender gap where endometriosis alone affects roughly 10% of reproductive-age women yet historically took 7–10 years to diagnose through invasive laparoscopy. The 2026 frontier concentrates on four directions: non-invasive endometriosis diagnostics from saliva miRNA (Ziwig Endotest, fast-track reimbursed for 25,000 patients across 80 French medical centres since February 2025, reading 109 miRNA markers with reported above-95% diagnostic accuracy in the ENDOmiRNA study); ovarian-longevity and fertility therapeutics that slow ovarian ageing to extend the natural fertility window and defer menopause; vaginal-microbiome live biotherapeutic products (LBPs) built on Lactobacillus crispatus consortia to restore an acidic vaginal pH below 4.5 and prevent bacterial vaginosis and preterm birth; and next-generation non-invasive prenatal testing (NIPT) that sequences cell-free fetal DNA (cfDNA) from maternal blood, where BGI’s NIFTY has analysed more than 10 million pregnancies. The stack is regulated end-to-end — FDA drugs and devices in the US, the EU In Vitro Diagnostic Regulation (IVDR 2017/746) Class C for miRNA tests plus EMA for therapeutics in Europe, and NMPA registration in China.

The key directions of FemTech biotech & women’s health are:

1. Non-invasive endometriosis diagnostics: saliva miRNA sequencing and menstrual-blood liquid biopsy (Ziwig Endotest, NextGen Jane Smart Tampon) that replace diagnostic laparoscopy with a mail-in lab test returning a staged diagnosis in days.
2. Ovarian-longevity and fertility therapeutics: target discovery and non-hormonal drug design (Celmatix Resolve platform, now partnered with Gedeon Richter) to slow ovarian ageing, protect the follicle pool during chemotherapy, and defer menopause.
3. Vaginal-microbiome live biotherapeutics: L. crispatus consortia formulated as lyophilized vaginal LBPs (Novonesis/Lactobio) to restore a healthy acidic microbiome and reduce bacterial-vaginosis and preterm-birth risk.
4. Non-invasive prenatal testing (NIPT): high-throughput cfDNA sequencing of fetal DNA in maternal blood (BGI NIFTY) to screen for fetal chromosomal aneuploidies early in pregnancy.

Sectoral value chain

[Sample sourcing] ──> [Omics profiling] ──> [AI biomarker decoding]
      │                     │                       │
(saliva, menstrual,     (RNA-seq, cfDNA)    (miRNA → disease score)
 venous blood kits)                                   │
                                                       ▼
[Clinical delivery] <─── [GMP formulation] <─── [Therapeutic R&D]
(reimbursement, CE-IVD)     (LBP, peptide)     (ovarian, microbiome)

Value chain levels

Cross-cutting technologies of the sector:

• Saliva miRNA liquid biopsy: high-sensitivity profiling of non-coding microRNAs carried in salivary exosomes; a 109-miRNA panel reports endometriosis with diagnostic accuracy above 95%, replacing invasive laparoscopy with a mail-in test.
• L. crispatus live biotherapeutics: vaginal LBPs built on L-microbe-producing L. crispatus strains that hold vaginal pH below 4.5, blocking colonization by pathogenic anaerobes and cutting the risk of ascending reproductive infections and preterm birth.
• Anti-Müllerian hormone (AMH) engineering: recombinant AMH molecules and receptor agonists that temporarily place the ovary in a dormant state during chemotherapy or to control ovarian reserve, preserving female fertility.

02US

The United States holds the deepest FemTech venture base and the largest dedicated women’s-health pharma, commercializing ovarian-longevity therapeutics and molecular tampons while NIH grants de-risk early diagnostics.

Ovarian-longevity R&D, molecular tampon, dedicated FemTech pharma, NIH funding

• Celmatix and ovarian longevity: Celmatix’s Resolve platform uses multi-omic and clinical big data to map ovarian reserve and design non-hormonal candidates against ovarian ageing, and Hungarian pharma Gedeon Richter has acquired Celmatix’s women’s-health drug-discovery portfolio spanning fertility and endometriosis programs.
• NextGen Jane (Smart Tampon): NextGen Jane turns an ordinary tampon into a liquid-biopsy device, isolating endometrial cells and extracellular RNA from menstrual blood for non-invasive endometriosis and fibroid diagnosis; it validated a DNA/RNA/microbiome menstrual system in 2025 and received its second NIH SBIR Direct-to-Phase-II grant in May 2025.
• Organon (NYSE: OGN): spun out of MSD/Merck in 2021, Organon is the largest dedicated women’s-health company, reporting $6.2 billion in full-year 2025 revenue and $1.91 billion adjusted EBITDA (30.7% margin), with the postpartum-haemorrhage Jada System and the Nexplanon contraceptive implant.

03CN

China develops FemTech under explicit state policy to support fertility and cut maternal and infant mortality, with BGI Genomics running the world’s largest non-invasive prenatal testing programme and CAS institutes researching premature ovarian insufficiency.

NIPT leadership (BGI Genomics), CAS reproductive institutes, vaginal probiotics

• BGI Genomics (NIFTY): BGI Genomics’ NIFTY cfDNA test has analysed more than 10 million pregnancies worldwide, screening fetal trisomies (including Down syndrome) from maternal-blood cfDNA, and the upgraded NIFTY version has entered NMPA priority review.
• CAS reproductive institutes: the Shanghai institutes of the Chinese Academy of Sciences coordinate research into premature ovarian insufficiency (POI) and early menopause, and Chinese clinics run trials of collagen-scaffold mesenchymal-stem-cell therapy to regenerate the endometrium after injury.
• Vaginal-probiotic production: Chinese manufacturers produce large volumes of reproductive-health probiotics and are writing vaginal-microecology standards into national gynaecology guidelines.

04EU

The European Union is the global regulatory and technological pioneer of non-invasive endometriosis liquid biopsy, pairing the breakthrough Ziwig salivary test with strict IVDR Class C oversight and a live-biotherapeutic pipeline from Novonesis.

Ziwig Endotest (France), Novonesis/Lactobio (Denmark), CE-IVDR Class C

• Ziwig Endotest: the French biotech Ziwig built the first salivary endometriosis test, sequencing 109 salivary miRNA markers and decoding them with AI; France granted fast-track reimbursement for 25,000 patients across 80 medical centres in February 2025, and the ENDOmiRNA study — the largest saliva-biomarker study worldwide — confirmed its accuracy in December 2025.
• Novonesis (ex-Lactobio), Denmark: Novonesis (which absorbed the Lactobio team via Chr. Hansen) runs a multi-strain L. crispatus vaginal synbiotic programme, with a randomized placebo-controlled trial (NCT05659745) and the VIBRANT Phase 1 trial of L. crispatus live biotherapeutics for bacterial vaginosis, using machine learning to predict probiotic function from vaginal strains.
• IVDR Class C: European regulators classify early miRNA diagnostics under the IVDR 2017/746 as Class C, requiring exhaustive multi-centre validation studies and independent notified-body audit before CE marking — the bar Ziwig cleared for its reimbursement.

05Leading companies and research institutes

06Tech stack and innovations

The FemTech biotech stack joins a small-RNA/cfDNA sequencing core, an AI biomarker-decoding layer, and a live-biotherapeutic formulation layer.

1. Small-RNA (miRNA) extraction and NGS library preparation:
   • Silica magnetic nanoparticles with tuned porosity capture the delicate 19–24-nucleotide miRNA fraction while washing away ribosomal and genomic RNA, and a Pippin-Prep-style preparative gel electrophoresis size-selects the 140–160 bp miRNA-plus-adapter library, stripping PCR adapter-dimer contamination.
2. AI miRNA-signature decoding:
   • A trained machine-learning model (SVM / random forest) takes the normalized expression of the 109-miRNA endometriosis panel and outputs a disease probability, stage and phenotype, turning a saliva sample into a clinical diagnosis without laparoscopy.
3. Lyophilized L. crispatus live biotherapeutics:
   • L. crispatus biomass is freeze-dried with protectant sugars (trehalose, sorbitol) on a temperature profile that prevents acid damage to cell walls, holding a stable titre above 1 billion CFU per suppository for ambient storage.

07Value chains and production pipelines

Diagnostic miRNA pipeline of the Ziwig Endotest (ISO 13485 / GMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Saliva collection into │ ───> │ 2. Automated total +      │
│    RNA-stabilizer tube    │      │    small-RNA extraction    │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Precision size-        │ <─── │ 3. Small-RNA library prep │
│    selection (gel)        │      │    (adapter ligation, RT)  │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. NGS sequencing         │ ───> │ 6. AI 109-miRNA score &   │
│    (Illumina NextSeq)     │      │    clinical report        │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Saliva collection and transport

The patient spits into a Ziwig Endotest tube; on cap-rotation a stabilizing buffer of chaotropic salts and RNase inhibitors is released, instantly denaturing salivary proteins and preserving exosomal extracellular RNA, and the tube is mailed to the central accredited laboratory.

Stage 2: Automated total and small-RNA extraction

A robotic liquid handler (e.g. Hamilton Microlab) transfers stabilized saliva to an extraction plate; isopropanol and silica magnetic beads bind RNA in chaotropic salt, three alcohol washes remove salts, proteins and mucins, and RNA is eluted in RNase-free water with quality checked on an Agilent Bioanalyzer for a crisp small-RNA peak.

Stage 3: Small-RNA library preparation

A T4 RNA ligase attaches a 3’ and then a 5’ single-stranded RNA adapter to the small-RNA fraction; reverse transcription synthesizes cDNA, and 15 cycles of PCR with unique TruSeq index primers barcode each patient’s library.

Stage 4: Precision size selection

The PCR product is loaded onto a preparative gel-electrophoresis system (e.g. Pippin Prep); a built-in laser detects DNA fragments migrating through agarose, and at 140–160 bp the instrument switches current to collect the clean miRNA-library fraction while discarding adapter dimers at about 120 bp.

Stage 5: NGS sequencing

Purified libraries are quantified by qPCR, up to 96 patient libraries are pooled equimolarly, denatured, and loaded on an Illumina NextSeq 550 flow cell for single-end 50 bp sequencing at a depth of at least 5 million reads per sample.

Stage 6: AI signature and clinical report

Reads are demultiplexed, adapter-trimmed, quality-filtered and aligned to the miRBase small-RNA database and the hg38 reference; a count matrix of the 109-miRNA panel is fed to a trained SVM model that outputs endometriosis probability, stage and phenotype; a clinical geneticist verifies the report and returns it to the gynaecologist, often sparing the patient a diagnostic laparoscopy.